5-alpha reductase

(redirected from 5 alpha-reductase)
Also found in: Wikipedia.

5-alpha reductase

(al'fa re-duk'tās),
Intracellular enzyme that converts testosterone to 5-alpha dihydrotestosterone (DHT). Two distinct isoforms are known in humans and laboratory animals.

5-alpha reductase

An enzyme that converts testosterone to dihydrotestosterone.
See also: reductase
References in periodicals archive ?
A 5 alpha-reductase enzyme inhibitor, Dutasterid, works by reducing production of a hormone called dihydrotestosterone (DHT).
PURPOSE: We reviewed the physiological and pathogenic role of dihydrotestosterone (DHT), evidence for the beneficial effects of decreasing DHT through 5 alpha-reductase inhibition and the effects of altering the androgen balance with these agents.
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.
URINOZINC Plus' patented formula was developed by urologists and is specifically designed for alleviating the symptoms of BPH, for use as a nutritional supplement by men who are on prostate-benefiting drugs including alpha-adrenergic blockers and 5 alpha-reductase and for use as a nutritional support for individuals using antibiotics for bacterial prostatitis.
Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors.
The 5 alpha-reductase inhibitors (dutasteride and finasteride) are appropriate and effective treatments for patients with LUTS associated with demonstrable prostatic enlargement.
Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas.
Finasteride belongs to a class of Type II 5 alpha-reductase inhibitors used in the treatment of enlarged prostate glands.
Changes in brain aromatase and 5 alpha-reductase activities correlate significantly with seasonal reproductive cycles in goldfish (Carassius auratus).
GlaxoSmithKline today announced the initiation of a new international clinical trial evaluating dutasteride, a dual 5 alpha-reductase inhibitor (5 A-RI), in combination with the most widely prescribed alpha-blocker, tamsulosin, in men with benign prostatic hyperplasia (BPH).
Avodart, a 5 alpha-reductase inhibitor (5 A-RI), arrests the BPH disease process - unlike the most commonly prescribed BPH treatment, alpha-blockers, which are indicated only for symptom improvement.